REVIEW article
Front. Drug Deliv.
Sec. Technological and Methodological Advances in Drug Delivery
Volume 5 - 2025 | doi: 10.3389/fddev.2025.1644633
This article is part of the Research TopicRising Stars in Drug DeliveryView all articles
Strategies for delivering drugs across the blood-brain barrier for the treatment of neurodegenerative diseases
Provisionally accepted
- 1Qingdao University, Qingdao, China
- 2The Affiliated Hospital of Qingdao University, Qingdao, China
- 3Qingdao Stomatological Hospital, Qingdao, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The blood-brain barrier (BBB) restricts development of drug delivery systems for brain, which hinders the potential applications of numerous pharmaceutical agents for treating central nervous system (CNS) diseases. A number of drug delivery systems have been developed to enhance the capacity of drugs to cross BBB. A detailed introduction of the structure and function of BBB was given based on the mechanism of BBB, while comparing with the pathological changes of BBB in neurodegenerative diseases (NDDs), including activation of endothelial cells, the loose of tight junction and increase of BBB permeability. The liposomes, polymer nanoparticles and other novelty approaches for treating NDDs were summarized. Here, we provide a novel perspective to classify the strategies of drug delivery system as passive targeting and active targeting according to their mechanisms. The potential of clinical translational for drug delivery systems in NDDs was explored and underscored the imperative of safety and verification through clinical trials. In summary, this review proposed current developments of drug delivery systems and discussing the potentials of drug delivery systems in clinical translational. which bring new breakthroughs for treating NDDs.
Keywords: Blood-Brain Barrier, Drug delivery, Neurodegenerative Diseases, nanocarriers, targeted delivery
Received: 10 Jun 2025; Accepted: 12 Aug 2025.
Copyright: © 2025 Zhang, Fu, Wang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tong Wu, Qingdao University, Qingdao, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.